Clinical trial
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
NCT02332980 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 19, 2015
- Completion date
- January 4, 2022
- Enrollment
- 65 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent b-cell non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent marginal zone lymphoma, recurrent nodal marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent splenic marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory b-cell non-hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, refractory follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory nodal marginal zone lymphoma, refractory small lymphocytic lymphoma, refractory splenic marginal zone lymphoma, refractory waldenstrom macroglobulinemia, richter syndrome, waldenstrom macroglobulinemia